S&P 500   4,668.51 (+1.61%)
DOW   35,237.85 (+0.97%)
QQQ   399.69 (+2.17%)
AAPL   160.75 (+2.51%)
MSFT   337.80 (+2.46%)
FB   338.70 (+1.68%)
GOOGL   2,909.18 (+2.30%)
AMZN   3,589.41 (+2.42%)
TSLA   1,132.43 (+4.67%)
NVDA   330.46 (+4.90%)
BABA   132.07 (-0.96%)
NIO   39.99 (+0.00%)
CGC   11.18 (-4.36%)
AMD   159.65 (+3.13%)
GE   98.27 (+0.44%)
MU   84.90 (+1.77%)
T   24.03 (-0.78%)
F   19.83 (+0.41%)
DIS   146.66 (-0.98%)
ACB   6.51 (-4.12%)
AMC   36.67 (-2.55%)
PFE   53.69 (-0.57%)
BA   198.45 (-0.38%)
S&P 500   4,668.51 (+1.61%)
DOW   35,237.85 (+0.97%)
QQQ   399.69 (+2.17%)
AAPL   160.75 (+2.51%)
MSFT   337.80 (+2.46%)
FB   338.70 (+1.68%)
GOOGL   2,909.18 (+2.30%)
AMZN   3,589.41 (+2.42%)
TSLA   1,132.43 (+4.67%)
NVDA   330.46 (+4.90%)
BABA   132.07 (-0.96%)
NIO   39.99 (+0.00%)
CGC   11.18 (-4.36%)
AMD   159.65 (+3.13%)
GE   98.27 (+0.44%)
MU   84.90 (+1.77%)
T   24.03 (-0.78%)
F   19.83 (+0.41%)
DIS   146.66 (-0.98%)
ACB   6.51 (-4.12%)
AMC   36.67 (-2.55%)
PFE   53.69 (-0.57%)
BA   198.45 (-0.38%)
S&P 500   4,668.51 (+1.61%)
DOW   35,237.85 (+0.97%)
QQQ   399.69 (+2.17%)
AAPL   160.75 (+2.51%)
MSFT   337.80 (+2.46%)
FB   338.70 (+1.68%)
GOOGL   2,909.18 (+2.30%)
AMZN   3,589.41 (+2.42%)
TSLA   1,132.43 (+4.67%)
NVDA   330.46 (+4.90%)
BABA   132.07 (-0.96%)
NIO   39.99 (+0.00%)
CGC   11.18 (-4.36%)
AMD   159.65 (+3.13%)
GE   98.27 (+0.44%)
MU   84.90 (+1.77%)
T   24.03 (-0.78%)
F   19.83 (+0.41%)
DIS   146.66 (-0.98%)
ACB   6.51 (-4.12%)
AMC   36.67 (-2.55%)
PFE   53.69 (-0.57%)
BA   198.45 (-0.38%)
S&P 500   4,668.51 (+1.61%)
DOW   35,237.85 (+0.97%)
QQQ   399.69 (+2.17%)
AAPL   160.75 (+2.51%)
MSFT   337.80 (+2.46%)
FB   338.70 (+1.68%)
GOOGL   2,909.18 (+2.30%)
AMZN   3,589.41 (+2.42%)
TSLA   1,132.43 (+4.67%)
NVDA   330.46 (+4.90%)
BABA   132.07 (-0.96%)
NIO   39.99 (+0.00%)
CGC   11.18 (-4.36%)
AMD   159.65 (+3.13%)
GE   98.27 (+0.44%)
MU   84.90 (+1.77%)
T   24.03 (-0.78%)
F   19.83 (+0.41%)
DIS   146.66 (-0.98%)
ACB   6.51 (-4.12%)
AMC   36.67 (-2.55%)
PFE   53.69 (-0.57%)
BA   198.45 (-0.38%)
NASDAQ:PRFX

PainReform Stock Forecast, Price & News

$1.94
-0.01 (-0.51%)
(As of 11/29/2021 12:18 PM ET)
Add
Compare
Today's Range
$1.85
$1.95
50-Day Range
$1.91
$3.21
52-Week Range
$1.75
$7.84
Volume
2,165 shs
Average Volume
692,129 shs
Market Capitalization
$20.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.53
30 days | 90 days | 365 days | Advanced Chart
Receive PRFX News and Ratings via Email

Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter.


About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Headlines

Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely?
November 22, 2021 |  finance.yahoo.com
Short Interest in PainReform Ltd. (NASDAQ:PRFX) Drops By 31.7%
November 19, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRFX
Fax
N/A
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.90 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$20.34 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/17/2022

MarketRank

Overall MarketRank

1.00 out of 5 stars

Medical Sector

1253rd out of 1,392 stocks

Pharmaceutical Preparations Industry

603rd out of 670 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












PainReform (NASDAQ:PRFX) Frequently Asked Questions

Are investors shorting PainReform?

PainReform saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 74,400 shares, an increase of 98.4% from the October 31st total of 37,500 shares. Based on an average daily volume of 553,800 shares, the short-interest ratio is presently 0.1 days. Approximately 1.5% of the company's stock are sold short.
View PainReform's Short Interest
.

When is PainReform's next earnings date?

PainReform is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for PainReform
.

How were PainReform's earnings last quarter?

PainReform Ltd. (NASDAQ:PRFX) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.25.
View PainReform's earnings history
.

Who are PainReform's key executives?

PainReform's management team includes the following people:
  • Dr. Ehud Geller Ph.D., Exec. Chairman
  • Mr. Ilan Hadar M.B.A., MBA, CEO & CFO (Age 52)
  • Dr. Sigal Aviel, Chief Operating Officer (Age 57)
  • Prof. Eli Hazum Ph.D., CTO & Director
  • Dr. Stephen A. Cooper D.M.D Ph.D., Exec. VP of Devel.

What other stocks do shareholders of PainReform own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PainReform investors own include Novartis (NVS), AbbVie (ABBV), American Airlines Group (AAL), Bank of America (BAC), Bristol-Myers Squibb (BMY), Clorox (CLX), Cisco Systems (CSCO), CVS Health (CVS), Delta Air Lines (DAL) and DocuSign (DOCU).

When did PainReform IPO?

(PRFX) raised $20 million in an initial public offering (IPO) on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar acted as the underwriters for the IPO.

What is PainReform's stock symbol?

PainReform trades on the NASDAQ under the ticker symbol "PRFX."

Who are PainReform's major shareholders?

PainReform's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.22%) and Citadel Advisors LLC (0.11%).

Which institutional investors are selling PainReform stock?

PRFX stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC.

Which institutional investors are buying PainReform stock?

PRFX stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC.

How do I buy shares of PainReform?

Shares of PRFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PainReform's stock price today?

One share of PRFX stock can currently be purchased for approximately $1.94.

How much money does PainReform make?

PainReform has a market capitalization of $20.34 million.

How many employees does PainReform have?

PainReform employs 2 workers across the globe.

What is PainReform's official website?

The official website for PainReform is www.painreform.com.

How can I contact PainReform?

The company can be reached via phone at 972-9960-1901 or via email at [email protected].


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.